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Breast cancer is the leading cause of cancer-associated mortality in women, with elevated incidence in developing countries. This
retrospective study included all 122 patients diagnosed with breast cancer from January 2003 to December 2008 in the Sultanate
of Oman. Age at presentation was 47.41 years (SD±12.88), with one-third of patients younger than 40 years. The majority of
patients presented with stage III (41.2%) and IV (18.2%) breast cancer. T size (P = .023), skin involvement (P = .003), and stage
at presentation (P = .004) were signiﬁcantly associated with overall survival. Skin involvement at presentation (P = .003), T size
(P = .09), lymph node status (P = .013), and stage (P = .003) were strong predictors of relapse-free survival. Patients had a
5-year survival of 78%, compared to 64% of breast cancer patients diagnosed between 1996 and 2002 identiﬁed in our previously
published study. Thus, despite Omani breast cancer patients continuing to present with advanced breast cancer, survival rates have
signiﬁcantly improved.
1.Introduction
Breast cancer is the leading cause of cancer-related mortality
in women worldwide. Almost half of annually diagnosed
females with breast cancer belong to developing countries,
where they present at a younger age with advanced-stage
disease. These women also have poor overall outcomes
compared to women in developed countries. The advanced
stage of presentation of breast cancer in developing countries
was attributed to a lack of mass education and screening
programs, poverty, poor access to health care facilities, lack
of expertise, and poor country infrastructure [1–7].
Itisanestablishedfactthatethnicdisparities aﬀectbreast
cancer outcome. Despite correction of well-known factors
associatedwithbreastcancer-relatedoutcome,suchastumor
size, lymph node status, hormone receptor expression,
Her2/neu gene expression, stage, and age at presentation,
racial diﬀerences were prominent as prognostic factors and
have been associated with genetic diﬀerences between races.
Investigatorshaveproposedmultiplereasonstoexplainthese
diﬀerences between races [1, 8–12].
The Sultanate of Oman is a developing Asian country in
the Gulf Region with a developing health care system. Like
women worldwide, Omani women also share major burden
of breast cancer incidence and associated mortality. One out
of ﬁve Omani women is diagnosed with breast cancer in her
lifetime, and the age-standardized incidence rate is 15.6 per
100,000. In our last reported study, we found that age at
diagnosis is younger in Oman than in the western world, and
the majority of patients present at advanced stages of disease
(III and IV) [1].
In our last study, we reported the clinicopathologic
features, such as treatment modalities, outcome, and asso-
ciated prognostic factors for Omani women, that have a
diagnosis of breast cancer between the years of 1996 and
2002. The results of this previous study revealed that patients
in Oman presented at a younger age and with an advanced
stage of disease. Furthermore, there is an underutilization of
neoadjuvant (NA) therapy with 5-year relapse-free survival
(RFS) and 5-year overall survival (OS) of 64% and 62%,
respectively [1]. In this present paper, we analyzed data
retrospectively to determine if OS had improved. We also
analyzed whether the trends of disease presentation or2 Journal of Oncology
associated outcome had changed between 1996–2002 and
2003–2008.
2. Patientsand Methods
We analyzed patient data using the computerized hospital
information system of our university hospital for patients
admitted with the diagnosis of invasive breast cancer from
January 2003 to December 2008. Our hospital (Sultan
Qaboos University Hospital) is one of the two main hospitals
providing cancer treatment in the Sultanate of Oman.
Among the patients included in this retrospective data, the
majority were diagnosed and treated in this hospital, but
some patients presented either after being diagnosed in other
hospitals or after undergoing surgery at peripheral hospitals.
Our pathology department reviewed almost all histopatho-
logical specimens for conﬁrmation of diagnosis and immune
staining of tissue for estrogen receptor (ER), progesterone
(PgR), and Her2/neu status. Due to the advanced stage of
breast cancer at presentation, the breast cancer stage in most
patients was determined by CT scans of the chest, abdomen,
and pelvis, as well as with bonescans.
The records of all patients with a conﬁrmed diagnosis
of invasive breast cancer were reviewed, and a database was
created. Variables were identical to those presented in our
previous published study and included age and sex; date of
diagnosis; side of involved breast; histopathological type of
tumor; clinical and pathological tumor size; pathological or
clinicalinvolvementofskinornippleareolacomplex;clinical
and pathological lymph node involvement; tumor grade;
marker status of tumor, including ER, PgR, and Her2/neu
status; clinical and pathological stage of the patients. Records
were also reviewed for the date of last followup exam, date
and site of relapse, and date of death, when relevant.
Relapse-freesurvival(RFS)wasmeasuredfromdiagnosis
to the date of documented relapse and was censored at the
date of last followup. Overall survival (OS) was measured
from the date of diagnosis to the date of death and censored
by the last date of followup.
Kaplan-Meir curves were used to determine OS and RFS
and the log-rank test was used for comparison analysis.
The Cox proportional hazard model was used for univariate
analysis with the variables included being age, menopausal
status, tumor size, lymph node status, tumor grade, and
estrogen receptor status. The Cox model was used for
multivariate analysis including all statistically signiﬁcant
factors as per univariate analysis. All reported P-values
herein are nominal 2-sided. Data analysis was performed
using SPSS version 16.
3. Results
3.1. Clinical and Pathological Features. A total of 122 patients
were identiﬁed with a diagnosis of invasive breast cancer.
The majority of patients were of Omani origin 108 (88.5%).
The mean age of all patients was 47.41 (SD ± 12.88) years
and 3 of 122 patients were male (Table 1). Almost one-third
(32%) of the patients were younger than 40 years of age
at the time of diagnosis and 55.7% were premenopausal.
More than half (55.7%) of patients underwent nonbreast
conserving surgery. Twenty-nine patients (23.7%) received
neoadjuvant(NA)chemotherapy,whichisequivalentto47%
of the patients who presented with locally advanced disease
stage (stage IIB to IIIC). Of the total, 38% of tumors were
negative for hormone receptor (ER and PgR) expression,
and 21% were positive for the Her2/neu gene detected by
immunohistochemistry. An additional 15% of patient data
regarding Her2 status were missing.
External beam radiotherapy was administered to 73.8%
of patients. All patients were treated locally, diﬀering from
our previous paper due to the fact that radiation facilities
were not available in Oman at the time.
Table 2 summarizes the patients’ clinical and patho-
logical stage of breast cancer. Mean clinical tumor size
was 5.3cm (±2.7cm), while mean pathological size was
3.8cm (±2.7cm) which is almost identical to our previous
paper (5.4cm (S.D. 3.86) and 4.6cm (S.D. 3.29), resp.).
Forty-four patients (36%) had a tumor size of >5.5cm.
Among those 44 patients with large tumor size, 34 patients
presented with clinical T4 disease, versus only 9 patients
who presented with a clinical T1 lesion (38 and 22 patients,
resp., were reported to have clinical T4 and T1 lesions, resp.,
in our last paper). More than half of patients presented
with advanced disease, with stages III and IV diagnosed in
41.2%and18.5%ofpatients,respectively(34.9%and15.8%,
resp., during years 1996–2002). Of the 89 patients (73%
of total) who underwent axillary lymph node dissection,
including 29 patients after NA chemotherapy, 18 (20%) had
N3 (≥10 positive lymph nodes) disease, while 18 (20%)
and 19 (21%) patients had N2 (4 to 6 positive lymph
nodes) and N1 (1–3 positive lymph nodes), respectively.
Among the 29 patients who received NA chemotherapy,
9 (31.0%) patients showed complete pathological response
in the primary lesion and axillary lymph nodes (pCR),
and 18 patients had N0 upon pathological exploration. All
patients who were treated with neoadjuvant chemotherapy
receivedanthracyclinesfollowedbytaxanesandtrastuzumab
where indicated, which resulted in signiﬁcant pathological
responses and reason for better outcome than our previous
study as patients were treated with anthracycline or CMF-
(cyclophosphamide, methotrexate, and ﬂuorouracil) based
regimens in the past paper. Ductal carcinoma was a major
histopathologicalsubtype,identiﬁedin120(98.4%)patients,
withlobularcarcinomaandcarcinosarcomaidentiﬁedinone
patient each. Grade III disease was identiﬁed in 43 (35.2%)
patients, while 60 (49.2%) and 10 (8.2%) patients had grade
I Ia n dg r a d eId i ﬀerentiation, respectively (in 35.5%, 48.1%,
and 16.4% patients, respectively, during years 1996–2002 as
reported in our last paper). Information was missing for
the remaining nine patients. Hormone receptor status was
available for 118 (96.7%) patients and, among those, 71
(60.2%) and 74 (62.7%) patients expressed estrogen and
progesterone receptors, respectively. Information regarding
Her2/neu status was available for 103 (84.4%) patients,
revealing that 26 (21.3%) had Her2 positive disease. Of
all the 26 patients who were positive for Her2/neu gene,
21 received trastuzumab. Seven patients were treated in
neoadjuvant setting with pCR in 2 patients and more thanJournal of Oncology 3
Table 1: Clinical features and treatment modalities used for all 122 patients with invasive breast cancer in Oman between January 2003 and
December 2008.
Clinical characteristics Number Percentage Number Percentage
Period 2003–2008 Period 1996–2002
Gender
Female 119 97.5 150 98.7
Male 3 2.5 21 . 3
Age
≤40 39 32 31 20.4
41–50 36 29.5 46 30.3
51–60 31 25.4 49 32.2
>60 16 13.1 26 17.1
Menopausal status (women)
Premenopausal 68 57.1 72 48.0
Menopausal 51 42.8 78 52.0
Side of involved breast
Left 65 53.2 74 48.7
Right 54 44.3 76 50.0
Bilateral 3 2.5 21 . 3
Surgery
Modiﬁed radical mastectomy 68 55.7 100 65.8
Breast conservation surgery 43 35.2 40 26.3
Lumpectomy or biopsy only — — 12 7.9
Surgery not done (patient refusal or stage IV disease) 11 9 — —
Chemotherapy∗
Neoadjuvant¶ 29 23.7 20¤ 13.2
Adjuvant 65 53.2 65 (17) 42.8
FEC 26 40 44 (13) / =
AC → Docetaxel ± trastuzumab 24 37 4
Miscellaneous (AC, Paclitaxel, TAC, or CMF) 15 23 11 (4)
Palliative 18 14.75 — —
Chemotherapy refused 7 5.73 — —
Missing information 3 2.45 — —
Radiotherapy 90 73.8 96 63.1
Hormone treatment
Tamoxifen or Aromatase inhibitors 85 69.7 115 (14)
§ 75.7 (9.3)
∗A = Adriamycin, C = Cyclophosphamide, E = Epirubicin, F = Fluorouracil, M = Methotrexate, T = Docetaxel. ¶AC/FEC followed by paclitaxel or
docetaxel ± trastuzumab, where indicated.
¤All received anthracycline (AC/FEC/FAC) regimens, / =The numbers in brackets refer to patients with metastatic disease treated with chemotherapy and/or
hormonal treatment. All these patients were treated with anthracycline-based regimens (AC/FEC/FAC). All but 3 patients were treated with tamoxifen;
aromatase inhibitors were not in use during that period. 3 patients were treated with goserelin.
good partial response in the remaining ﬁve. Five patients
received trastuzumab in palliative setting for stage IV disease
whiletheremaining9patientsweretreatedwithtrastuzumab
in adjuvant setting.
3.2. Survival and Prognostic Factors. With a mean followup
duration of 54 months, 27 patients died, and 4 patients
were lost to followup. Among the patients that died, 10
deaths were of the metastatic group and 17 were of the
nonmetastatic group. Among the 33 patients who expe-
rienced a relapse, 18 of those patients subsequently died
from their disease. In nine patients, disease relapse led to
bone metastases, and ﬁve patients had brain metastases;
lungs,pleura,liver,andlocalrelapsewerealsomanifestations
identiﬁed at the time of disease recurrence.
Seventy-six patients were living at the end of the study,
with no evidence of disease. Additional 15 patients have
experienced persistent disease, with 12 of those 15 patients
belonging to the metastatic group.
Skin involvement at presentation (P = .003), T size
(P = .023), and stage (P = .004) were signiﬁcant factors
associated with OS as determined by univariate analysis.
Additionally, skin involvement at presentation (P = .003), T
size (P = .09), lymph node status (P = .013), and stage (P =
.003) were strong predictors associated with RFS (Table 3).
Stage at presentation was the only signiﬁcant factor4 Journal of Oncology
Table 2: Clinical and pathological staging of breast cancer.
Clinical stage∗ Clinical stage (N = 152) Pathological stage∗ Pathological stage† (N = 120)
Number Percentage Number Percentage Number Percentage Number Percentage
Period 2003–2008 Period 1996–2002 Period 2003–2008 Period 1996–2002
Primary tumor
Tis — — 21 . 3 —— 21 . 7
T 0 ———— 97 . 4— —
T1 9 8.4 22 14.5 19 18.4 12 10.0
T2 43 40.1 64 42.1 48 46.6 66 55.0
T3 21 19.6 38 25.0 27 26.2 32 26.7
T4 34 31.7 26 17.1 —— 86 . 6
Node
N0 (p¶ = 0) 26 24.5 94 61.8 44 41.5 37 30.8
N1 (p = 1–3) 33 31.1 36 23.7 24 22.6 40 33.3
N2 (p = 4–9) 29 27.3 12 7.9 18 17.0 29 24.2
N3 (p ≥ 10) 18 17 10 6.6 20 18.9 14 11.7
Stage
0— — 21 . 388 . 021 . 7
I7 6 13 8.6 10 10.0 12 10.0
II 46 39 60 39.5 39 38.0 56 46.7
III 43 36 53 34.9 41 41.0 50 41.7
IV∞ 22 18 24 15.8 ——— —
∗Data is not available for all patients in all categories, as some patients presented to this hospital after surgical intervention at peripheral hospitals, and
some of patients with stage IV disease did not undergo surgical intervention. ¶Denotes pathological nodal staging. ∞Only clinical stage is shown for stage IV
patients. †Pathological staging did not include neoadjuvant chemotherapy patients (N = 20) or those with metastatic disease who did not have breast surgery
(N = 12).
Table 3: Overall survival in all patients (N = 122) and relapse-free survival for patients in the nonmetastatic group (N = 100). Univariate
analysis performed using Cox proportional hazard’s model.
Variable Overall Survival Relapse-Free Survival
Risk ratio P-value Risk ratio P-value
Skin involvement at presentation
Negative 1 1
Positive 3.3 (1.5–7.5) .003 3.0 (1.4–6.4) .003
Pathological T-size
T1 + T2 1 1
T3 + T4 2.6 (1.1–6.1) .023 1.9 (0.9–3.9) .09
Stage
Ia n dI I 1 1
III /IV 5.4 (1.8–15.8) .004 3.7 (1.6–8.6) .003
Lymph nodes involved
Negative — — 1
Positive — — 2.9 (1.3–7.1) .013
(P = .006) for OS, as determined by multivariate Cox
regression analysis.
The 5-year OS for all patients was 78% (Figure 1). The
OS rates per stage were 100%, 87%, 62%, and 38% for
patients for stages I, II, III, and IV, respectively (Figure 2),
which is better in comparison with our previous paper in
which5-yearcumulativesurvivalforpatientspresentingwith
stage I, II, and III was 88%, 75%, and 59%, respectively
(Figures 1 and 2).
4. Discussion
The risk factors associated with poor outcome of breast
cancersuchasyoungageatpresentation,advancedstage,and
negative hormone receptor status have been well recognized.
In addition to these well-established risk factors, quality of
provided care, health awareness, access to the health care
system, and sociocultural beliefs are also closely linked to the


























10 20 30 40 50 60
Time since diagnosis (months)
Period 2003–2008
Period 1996–2002
Figure 1: 5-year overall survival curves in patients diagnosed with
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Figure 2: 5-year overall survival curves per stage at diagnosis for
those diagnosed in between (2003–2008) or (1996–2002).
enables the comparison with the conclusions formulated
in the previous paper. We can thus analyze the changes in
breast cancer patients with regards to presentation of clinical
and pathological features, treatment modalities used, and
outcome.
In total, 122 patients were diagnosed and treated for
invasive breastcancerin Oman. Consistent with the previous
published paper, we observed that the age at presentation
was still quite young, with a mean age of 47.41 (±12.88)
years. Signiﬁcantly, this age at presentation is almost a
decade younger than women who present with invasive
breast cancer and are from developed countries. In contrast,
the age at presentation in the present study is relatively
consistent between Oman and other developing countries,
including neighboring Arab countries [2, 4, 6, 7, 13–15].
However, It should be highlighted that the presentation of
breast cancer at younger age in the developing world may
be due to younger population age distribution compared to
Western countries. The majority of patients in this study
were premenopausal, with 32% of women younger than 40
years of age and most having an advanced stage of disease
at the time of diagnosis. Furthermore, only 8% of patients
presented with a tumor smaller than 2cm, which is also in
contrast to the data from aﬄuent countries, but consistent
with data from neighboring regional and other developing
countries[2–4,6,7,10,13–15].Themeanageatpresentation
in this present paper is a year younger compared to our
previously published paper. Furthermore, fewer patients
presented with stage I disease in this present paper, versus
the previous paper (8% versus 14.5%) [1]. More than one-
third (35.2%) of patients had tumors that were highgrade
and negative expression of hormone receptors (40%), both
ofwhicharefactorscontributingtotheaggressivenatureand
poor disease-associated outcome [2].
NA chemotherapy administered to patients for locally
advanced breast cancer is generally accepted as the treatment
of choice. This type of treatment is the reason for the
increasing number of breast-conserving surgeries (BCSs)
and is also associated with better OS [16–20]. However, data
from various papers regarding the treatment of breast cancer
in developing countries clearly demonstrates the under-
utilization of BCS. Furthermore, most patients undergo
unwarranted surgeries early in the course of the disease at
peripheral hospitals or have an advanced stage of tumor
growth [1, 2, 6, 7, 13, 14, 16]. Similar to our previous
published paper, the use of NA therapy was underutilized.
However, the use of NA therapy did show some improve-
ment, as in the present study, 29 patients (23.7%) were
treated with NA chemotherapy, which accounts for 23.7%
of total patients and 47% of patients who presented with
locally advanced disease stage (stage IIB to IIIC). All those
patients whoreceived NA chemotherapy showed an excellent
response, with 31% pCR in primary breast lesion and
62% pCR in recovered nodes. Adjuvant chemotherapy was
administered to 95% of patients, a rate which is signiﬁcantly
improved over the previous study, in which only 60.2% of
patients received adjuvant therapy.
We noticed better 5-year survival in patients of this
present study, in which patients had a 5-year OS of 78% as
compared to 64% in our last study [1] though disease stage
at presentation was almost identical and reasons for better
outcome are most likely due to introduction of frequent use
of taxanes and trastuzumab along with aromatase inhibitors
which were used very infrequently for patients reported
previously (Figure 2). The 5-year OS is similar or better in
comparison to studies regarding the eﬃcacy of breast cancer6 Journal of Oncology
treatment reported from other regional or developing coun-
tries [2, 6, 13]. Racial diﬀerences are now a known factor for
breast cancer-related clinical outcomes, excluding other risk
factors, as reported by two large database American studies.
O’Malley and colleagues studied racial disparities aﬀecting
breast cancer-related clinical outcomes among white Asian,
Hispanic, and African females diagnosed in California. The
results of this study revealed signiﬁcant diﬀerences in the 5-
year survival rate between these groups [12]. Furthermore,
Chu and coworkers reported the same survival diﬀerences in
youngblackandwhiteAmericanfemales[9].Inbothofthese
studies, besides diﬀerences attributed to race, investigators
uncovered signiﬁcant associations between socioeconomic
and education status of the patients as well. In addition to
other established risk factors of poor clinical outcome, stage
at presentation has a very signiﬁcant impact on OS. Patients
who present with stage IV breast cancer have an almost 14-
foldincreaseinriskofdeath,comparedtopatientsdiagnosed
with stage I disease [12]. This data is consistent with our
study, which reveals that patients who presented with stage
I disease had a 5-year OS of almost 100%, versus 38% for
patients with stage IV disease at presentation. Signiﬁcantly,
the 5-year OS for stage IV disease is almost twice as high as
reported in our previously published study regarding the OS
for metastatic disease [1].
Presentation at an advanced stage is common among
patientswithbreastcancerinundevelopedcountries.Socioe-
conomic issues, cultural barriers, and low literacy rates have
beenreportedasthefactorsresponsibleforadvancedstageof
presentation, in addition to lack of screening programs and
poor access to health care facilities [1, 5, 6, 11, 14, 15].
In conclusion, although the number of patients in this
study is relatively small, the study results show that patients
in Oman still present with advanced stages of disease at
a relatively young age. However, breast cancer patients
enrolled in the present study have markedly improved
RFS and OS. The improvement in RFS and OS is most
likely due to utilization of various treatment modalities,
including updated chemotherapy protocols and the use of
trastuzumab. Further comparisons between this and the
previous study reveal that Omani breast cancer patients still
presentwithadvanceddisease,poor tumordiﬀerentiation,at
a young age, and have a low percentage of hormone-positive
tumors, all of which are known factors associated with poor
overall disease outcome. Mass education programs, health
awareness measures, and establishing screening programs
are basic ways to decrease the disease burden and enable
diagnosis at earlier stages of disease.
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